Yeh, Albert C.
Li, Hui
Zhu, Yitan
Zhang, Jing
Khramtsova, Galina
Drukker, Karen
Edwards, Alexandra
McGregor, Stephanie
Yoshimatsu, Toshio
Zheng, Yonglan
Niu, Qun
Abe, Hiroyuki
Mueller, Jeffrey
Conzen, Suzanne
Ji, Yuan
Giger, Maryellen L.
Olopade, Olufunmilayo I. http://orcid.org/0000-0002-9936-1599
Funding for this research was provided by:
National Institutes of Health (U01CA195564)
University of Chicago Institute for Translational Medicine CTSA Pilot Grant Award
Dr. Ralph and Marian Falk Medical Research Trust (FP059463-01)
Ann Dudley Goldblatt Fellowship in Oncology (N/A)
Article History
Received: 11 December 2018
Accepted: 24 June 2019
First Online: 15 July 2019
Ethics approval and consent to participate
: This study was approved by the University of Chicago IRB Committee (#IRB15–1401) on November 9th, 2015. Consent was waived as all patient information was de-identified and no prospective tissue samples were collected.
: Not applicable.
: K.D. received royalties from Hologic.M.L.G. is a stockholder in R2/Hologic, co-founder and equity holder in Quantitative Insights, and receives royalties from Hologic, GE Medical Systems, MEDIAN Technologies, Riverain Medical, Mitsubishi, and Toshiba.O.I.O. is co-founder of Cancer IQ and on the Scientific Advisory Board for Tempus.